Skip to main navigation Skip to search Skip to main content

V H 1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Research output: Contribution to journalReview articlepeer-review

Abstract

Broadly neutralizing antibodies (bnAbs) are potential therapeutic molecules and valuable tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody responses to conserved epitopes can be highly convergent at the molecular level. Human antibodies targeting a number of viral antigens have often been found to utilize a restricted set of immunoglobulin germline genes in different individuals. Here we review recent knowledge on V H 1-69-encoded antibodies in antiviral responses to influenza virus, HCV, and HIV-1. These antibodies share common genetic and structural features, and often develop neutralizing activity against a broad spectrum of viral strains. Understanding the genetic and structural characteristics of such antibodies and the target epitopes should help advance novel strategies to elicit bnAbs through vaccination.

Original languageEnglish
Pages (from-to)149-159
Number of pages11
JournalCurrent Opinion in Virology
Volume34
DOIs
StatePublished - Feb 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Virology

Fingerprint

Dive into the research topics of 'V H 1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design'. Together they form a unique fingerprint.

Cite this